Francesca Lo Bianco
A5076605844- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Inflammatory Biomarkers in Disease Prognosis
- Immune cells in cancer
- Economic and Financial Impacts of Cancer
- Chronic Lymphocytic Leukemia Research
- Medication Adherence and Compliance
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Renal Transplantation Outcomes and Treatments
- Diabetes and associated disorders
- Ferroptosis and cancer prognosis
- Genetic factors in colorectal cancer
- Oral health in cancer treatment
- PARP inhibition in cancer therapy
- Pain Management and Opioid Use
- PI3K/AKT/mTOR signaling in cancer
- Inflammatory Myopathies and Dermatomyositis
- Pharmacological Effects and Toxicity Studies
Azienda USL di Bologna
2024
Azienda Ospedaliera Sant'Andrea
2023
Sapienza University of Rome
2020-2023
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
Underlying cancer pain has heterogenous aetiologies and mechanisms. It requires detailed comprehensive assessment, combined with personalized treatment. A multidisciplinary team is essential to providing the best management of at every disease stage, improving quality life outcomes in patients cancer. This narrative literature review emphasizes value all their preferred care setting. Real-life experiences are also reported witness efforts physicians properly manage pain. article part...
<p>Tumour micron-environment transcriptome analysis.</p>
Background: Although most of the analyses included transverse colon cancers (TCC) among right cancer (RCC), it is not completely clear if they present total similarities with RCC or have their specific features. Therefore, we an observational study to evaluate clinicopathological characteristics and survival data patients TCC. Methods: We retrospectively reviewed 450 RCC, whom 97 stages I–IV TCC were in this multicenter study; molecular parameters analyzed identify prognostic factors for...
<p>Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other medications/insulin therapy only, and metformin (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving medications: 18.9 months (95%CI: 15.9-21.6; 684 events), on only: 19.3 11.6-22.9; 48 metformin: 12.3 9.8-15.9; 100 events). B) Progression Free 8.2 7.1-9.4; 872 10.7 6.7-11.6; 61 7.9 5.1-10.1; 124 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on oral antidiabetic drugs therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), not receiving therapy 17.8 15.4 – 19.7; 750 events). B) Progression Free 8.2 6.2-11.4; 106 8.1 7.1 9.2; 951 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), not receiving 19.0 16.4 – 21.1; 732 events). B) Progression Free 7.9 5.3-10.1; 124 8.3 7.3 9.5; 933 events).</p>
<p>Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts diabetic samples (n = 11) versus non-diabetic controls 11). achieving the highest statistical significance (p value <0.05) highlighted presence corresponding gene name. Significantly downregulated transcripts: HRAS, Ras oncogene family (p=0.009); GTF3C1, transcription factor TFIIIC complex (p=0.018); LAG3, key immune...
<p>A) Heat map of the 770 transcripts analyzed with Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared non-diabetic controls (n=11). B) selected differently transcripted genes.</p>
<p>Scatter diagram with regression line summarizing the linear analysis between median baseline glycaemia (used as independent variable: x-axes) and NLR dependent y-axes). 133 patients included; A significant equation was found F(1,131)= 4.09, p = 0.04) an R2 of .030. NLR: neutrophil to lymphocyte ratio.</p>
<div>Abstract<p><b>Purpose:</b> No evidence exists as to whether type 2 diabetes (T2DM) impairs clinical outcome from Immune Checkpoint Inhibitors (ICI) in patients with solid tumors. <b>Experimental Design:</b> In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose lowering medications (GLM) for T2DM had shorter OS and PFS. We used targeted transcriptomics subset explore differences the tumor microenvironment...
<p>Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), not receiving medications: 17.5 26.6; 77 events). B) Progression Free 7.9 5.4 10.8; 113 10.1 7.7 13.8; C) Melanoma 22.9 12.0 NR; 25 NR 28.8 52 D) 11.4 4.9 23.4; 37 13.8 8.7 26.0; NR: reached; PSM: propensity score matching.</p>
<p>A) Heat map of the 770 transcripts analyzed with Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared non-diabetic controls (n=11). B) selected differently transcripted genes.</p>